Skip to main content

Day: May 14, 2021

FluroTech Announces Warrant Incentive Program Results Adding Over $1M to Company Treasury

CALGARY, Alberta, May 14, 2021 (GLOBE NEWSWIRE) — FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (“FluroTech” or the “Company“), a leading developer of spectroscopy-based technology, is pleased to announce that further to its news releases dated April 12, 2021 and May 7, 2021, the Early Warrant Exercise Incentive Program (“EWEIP“) has been completed and that 5,213,612 Warrants (as defined and described below) were exercised at the price of $0.22 per Warrant for gross proceeds to the Company of $1,146,994.64. In January of 2021, FluroTech closed, in two tranches, a non-brokered private placement of units (“Units“), for aggregate gross proceeds of $2,531,000. Each Unit comprised one common share in the capital of FluroTech (“Common Share“) and one Common Share purchase warrant...

Continue reading

Whole Earth Brands, Inc. Reports First Quarter 2021 Financial Results and Reiterates Full Year Guidance

First Quarter Branded CPG Segment Revenue Growth of 103%, Reflecting Strategic Acquisitions of Swerve and Wholesome; Both Acquisitions are Fully Integrated First Quarter Branded CPG Segment Proforma Organic Constant Currency Revenue Growth of 10% CHICAGO, May 14, 2021 (GLOBE NEWSWIRE) — Whole Earth Brands, Inc. (the “Company” or “we” or “our”) (Nasdaq: FREE), a global food company enabling healthier lifestyles by providing access to premium plant-based sweeteners, flavor enhancers and other foods through a diverse portfolio of trusted brands and delicious products, today announced its financial results for its first quarter ended March 31, 2021. The Company also reiterated fiscal year 2021 guidance. Irwin D. Simon, Executive Chairman, stated, “Our expanded portfolio of brands continues to outpace the category growth rate and is...

Continue reading

SL Green Signs Kyndryl to 22,500 Square Foot Lease at One Vanderbilt

New headquarters for future IBM spin-off brings the building to 81% leased NEW YORK, May 14, 2021 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE:SLG), Manhattan’s largest office landlord, today announced that Kyndryl has signed a 22,531-square-foot, 9-year lease, covering a portion of the 15th floor at One Vanderbilt Avenue for its new global headquarters. One Vanderbilt, the recently opened skyline-defining tower in the heart of East Midtown, is now 81% leased and remains on target to reach 90% leased by the end of this year. Kyndryl is the independent company that will be created following the separation of IBM’s Managed Infrastructure Services business, which is expected to occur by the end of 2021. Kyndryl designs, runs and manages the most modern, efficient and reliable technology infrastructure for the world’s most important...

Continue reading

ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update

Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 BARDA contract award provides up to $86.8 million for exebacase development Strong financial position with cash and investments of $87.2 million as of March 31, 2021 YONKERS, New York, May 14, 2021 (GLOBE NEWSWIRE) —  ContraFect Corporation (Nasdaq: CFRX) a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the first quarter ended March 31, 2021. “After an excellent first quarter of 2021, during which we received a considerable contract award from...

Continue reading

Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP

While the Phase 2/3 XIRIUS study did not meet its primary endpoint, data indicated positive trends in several prespecified secondary endpoints, such as a clinically relevant measure of visual acuity Biogen will communicate next steps for the program after analyzing the complete data set Currently there are no approved treatments for X-linked retinitis pigmentosa (XLRP), a rare inherited retinal disease that ultimately leads to blindness in most people with the conditionCAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced topline results from the Phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP). XLRP is a rare, inherited retinal disease that is associated with progressive...

Continue reading

Marathon Gold and Miawpukek First Nation Sign Memorandum of Understanding

TORONTO, May 14, 2021 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) and Miawpukek First Nation are pleased to announce that they have concluded a Memorandum of Understanding (the “MOU”) relating to the Environmental Assessment and development of the Valentine Gold Project located in central Newfoundland (the “Project”). The MOU was signed by Matt Manson, President and CEO of Marathon, and Miawpukek Chief Mi’sel Joe. The MOU provides for a process of ongoing engagement and consultation between Marathon and Miawpukek. This will include, amongst other things, the completion of a Traditional Knowledge/Traditional Land and Resource Use Study, funding for a community-based Liaison Officer, and the commencement of negotiations towards a Socio-Economic Agreement. Matt Manson, President and CEO of...

Continue reading

Solid Biosciences Provides First Quarter 2021 Business Update and Financial Results

– Patients 7 and 8 dosed in IGNITE-DMD Phase I/II clinical trial under new clinical protocol and second-generation SGT-001 manufacturing process; patient 8 experienced a serious adverse event – – Long-term biopsy data generated from the ongoing IGNITE DMD trial demonstrate durable microdystrophin expression as measured up to two years post dosing of SGT-001. Data to be presented today at ASGCT at 1:45 PM ET – – Continued research and innovation in musculoskeletal therapy generates next-generation DMD gene transfer candidate, SGT-003 – – Company ends Q1 with $268.5 million in cash; cash runway into Q4 2022 – – Company to hold conference call at 8:30am ET today – CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company...

Continue reading

Knight Therapeutics Reports First Quarter 2021 Results

MONTREAL, May 14, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2021. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q1 2021 Highlights FinancialsRevenues were $46,069, an increase of $230 or 1% over prior year. Gross margin generated of $20,580 or 45% compared to $19,860 or 43% in prior year. Adjusted EBITDA1 was $5,580, an increase of $2,383 or 75% over prior year. Interest income generated of $1,998 a decrease of $2,651 or 57% over prior year. Net income was $3,558 compared to net loss of $9,477 in prior year. Cash inflow from operations was $17,207...

Continue reading

Arena Minerals Announces Closing of Pampa Paciencia Property Sale to Astra Exploration

TORONTO, May 14, 2021 (GLOBE NEWSWIRE) — Arena Minerals Inc. (“Arena” or the “Company”) (TSX-V: AN) is pleased to announce completion of the sale of the Pampa Paciencia epithermal gold property (the “Property”), located in the Atacama region of northern Chile, to Astra Exploration Ltd (“Astra”), a private mineral exploration company. In consideration for Arena’s 80% ownership of the Property the Company has received 5.82 million of shares of Astra, representing 40% of the issued and outstanding shares of Astra with a deemed value of $1.6 million. Astra is a newly formed private mineral exploration company led by a proven management team with previous exploration success in discovering epithermal gold deposits. Astra intends to initiate a drill program on the Property and complete a going public transaction...

Continue reading

Extended Stay America Responds to Tarsadia and Highlights Compelling Reasons to Support the Transaction with Blackstone and Starwood Capital

Image 1Image 1Image 2Image 2Image 3Image 3Image 4Image 4Image 5Image 5Image 6Image 6Image 7Image 7New Letter to Shareholders Provides Comprehensive Discussion of the Transaction Rationale and the Immediate, Certain and Compelling $19.50 Per Paired Share Cash Value Addresses Tarsadia’s Misleading and Flawed Arguments Urges Shareholders Vote “FOR” the Transaction on the WHITE Company Proxy Card in Vote Set for June 8, 2021 CHARLOTTE, N.C., May 14, 2021 (GLOBE NEWSWIRE) — Extended Stay America, Inc. (“ESA”) and its paired-share REIT, ESH Hospitality, Inc. (“ESH” and, together with ESA, “Extended Stay” or the “Company”) (NASDAQ: STAY) today sent a new letter to shareholders detailing the strategic and economic factors...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.